11. SALE OF RESEARCH AND DEVELOPMENT ASSETS (Tables)

6 Months Ended

Oct. 31, 2018

Discontinued Operations and Disposal Groups [Abstract]

Discontinued operations summary

	Three Months Ended October 31,						Six Months Ended October 31,
	2018			2017			2018			2017
Operating expenses:
Research and development	$	–		$	3,650		$	–		$	7,216
Selling, general and administrative		–			343			–			782
Restructuring charges		–			330			–			330
Total operating expenses	$	–		$	4,323		$	–		$	8,328
Gain on sale of research and development assets before income taxes	$	1,000			–		$	1,000			–
Income tax expense		(261	)		–			(261	)		–
Income (loss) from discontinued operations, net of tax	$	739		$	(4,323	)	$	739		$	(8,328	)

The following table summarizes the assets and liabilities of discontinued operations as of October 31, 2018 and April 30, 2018:

	October 31, 2018		April 30, 2018
Assets:
Other receivables	$	–	$	5,000
Total assets of discontinued operations	$	–	$	5,000
Liabilities:
Accounts payable	$	–	$	32
Accrued clinical trial and related fees		117		3,613
Accrued payroll and related costs		174		614
Other liabilities		125		291
Total liabilities of discontinued operations	$	416	$	4,550